HDGF promotes gefitinib resistance by activating the PI3K/AKT and MEK/ERK signaling pathways in non-small cell lung cancer

Abstract Hepatoma-derived growth factor (HDGF) expression is associated with poor prognosis in non-small cell lung cancer (NSCLC); however, whether HDGF affects gefitinib resistance in NSCLC remains unknown. This study aimed to explore the role of HDGF in gefitinib resistance in NSCLC and to discove...

Full description

Bibliographic Details
Main Authors: Shuyan Han, Zhihua Tian, Huifang Tian, Haibo Han, Jun Zhao, Yanna Jiao, Chunli Wang, Huifeng Hao, Shan Wang, Jialei Fu, Dong Xue, Hong Sun, Pingping Li
Format: Article
Language:English
Published: Nature Publishing Group 2023-06-01
Series:Cell Death Discovery
Online Access:https://doi.org/10.1038/s41420-023-01476-0
_version_ 1797806852519493632
author Shuyan Han
Zhihua Tian
Huifang Tian
Haibo Han
Jun Zhao
Yanna Jiao
Chunli Wang
Huifeng Hao
Shan Wang
Jialei Fu
Dong Xue
Hong Sun
Pingping Li
author_facet Shuyan Han
Zhihua Tian
Huifang Tian
Haibo Han
Jun Zhao
Yanna Jiao
Chunli Wang
Huifeng Hao
Shan Wang
Jialei Fu
Dong Xue
Hong Sun
Pingping Li
author_sort Shuyan Han
collection DOAJ
description Abstract Hepatoma-derived growth factor (HDGF) expression is associated with poor prognosis in non-small cell lung cancer (NSCLC); however, whether HDGF affects gefitinib resistance in NSCLC remains unknown. This study aimed to explore the role of HDGF in gefitinib resistance in NSCLC and to discover the underlying mechanisms. Stable HDGF knockout or overexpression cell lines were generated to perform experiments in vitro and in vivo. HDGF concentrations were determined using an ELISA kit. HDGF overexpression exacerbated the malignant phenotype of NSCLC cells, while HDGF knockdown exerted the opposite effects. Furthermore, PC-9 cells, which were initially gefitinib-sensitive, became resistant to gefitinib treatment after HDGF overexpression, whereas HDGF knockdown enhanced gefitinib sensitivity in H1975 cells, which were initially gefitinib-resistant. Higher levels of HDGF in plasma or tumor tissue also indicated gefitinib resistance. The effects of HDGF on promoting the gefitinib resistance were largely attenuated by MK2206 (Akt inhibitor) or U0126 (ERK inhibitor). Mechanistically, gefitinib treatment provoked HDGF expression and activated the Akt and ERK pathways, which were independent of EGFR phosphorylation. In summary, HDGF contributes to gefitinib resistance by activating the Akt and ERK signaling pathways. The higher HDGF levels may predict poor efficacy for TKI treatment, thus it has the potential to serve as a new target for overcoming tyrosine kinase inhibitor resistance in combating NSCLC.
first_indexed 2024-03-13T06:13:39Z
format Article
id doaj.art-81a48af684bd4b0f8c19d5c3af641103
institution Directory Open Access Journal
issn 2058-7716
language English
last_indexed 2024-03-13T06:13:39Z
publishDate 2023-06-01
publisher Nature Publishing Group
record_format Article
series Cell Death Discovery
spelling doaj.art-81a48af684bd4b0f8c19d5c3af6411032023-06-11T11:05:57ZengNature Publishing GroupCell Death Discovery2058-77162023-06-019111210.1038/s41420-023-01476-0HDGF promotes gefitinib resistance by activating the PI3K/AKT and MEK/ERK signaling pathways in non-small cell lung cancerShuyan Han0Zhihua Tian1Huifang Tian2Haibo Han3Jun Zhao4Yanna Jiao5Chunli Wang6Huifeng Hao7Shan Wang8Jialei Fu9Dong Xue10Hong Sun11Pingping Li12Department of Integration of Chinese and Western Medicine, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & InstituteCentral Laboratory, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & InstituteCentral Laboratory, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & InstituteThe Tissue Bank, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & InstituteDepartment of Thoracic Medical Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & InstituteDepartment of Integration of Chinese and Western Medicine, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & InstituteDepartment of Oncology, Infectious Disease Hospital of Heilongjiang ProvinceDepartment of Integration of Chinese and Western Medicine, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & InstituteDepartment of Integration of Chinese and Western Medicine, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & InstituteDepartment of Integration of Chinese and Western Medicine, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & InstituteDepartment of Integration of Chinese and Western Medicine, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & InstituteDepartment of Integration of Chinese and Western Medicine, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & InstituteDepartment of Integration of Chinese and Western Medicine, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & InstituteAbstract Hepatoma-derived growth factor (HDGF) expression is associated with poor prognosis in non-small cell lung cancer (NSCLC); however, whether HDGF affects gefitinib resistance in NSCLC remains unknown. This study aimed to explore the role of HDGF in gefitinib resistance in NSCLC and to discover the underlying mechanisms. Stable HDGF knockout or overexpression cell lines were generated to perform experiments in vitro and in vivo. HDGF concentrations were determined using an ELISA kit. HDGF overexpression exacerbated the malignant phenotype of NSCLC cells, while HDGF knockdown exerted the opposite effects. Furthermore, PC-9 cells, which were initially gefitinib-sensitive, became resistant to gefitinib treatment after HDGF overexpression, whereas HDGF knockdown enhanced gefitinib sensitivity in H1975 cells, which were initially gefitinib-resistant. Higher levels of HDGF in plasma or tumor tissue also indicated gefitinib resistance. The effects of HDGF on promoting the gefitinib resistance were largely attenuated by MK2206 (Akt inhibitor) or U0126 (ERK inhibitor). Mechanistically, gefitinib treatment provoked HDGF expression and activated the Akt and ERK pathways, which were independent of EGFR phosphorylation. In summary, HDGF contributes to gefitinib resistance by activating the Akt and ERK signaling pathways. The higher HDGF levels may predict poor efficacy for TKI treatment, thus it has the potential to serve as a new target for overcoming tyrosine kinase inhibitor resistance in combating NSCLC.https://doi.org/10.1038/s41420-023-01476-0
spellingShingle Shuyan Han
Zhihua Tian
Huifang Tian
Haibo Han
Jun Zhao
Yanna Jiao
Chunli Wang
Huifeng Hao
Shan Wang
Jialei Fu
Dong Xue
Hong Sun
Pingping Li
HDGF promotes gefitinib resistance by activating the PI3K/AKT and MEK/ERK signaling pathways in non-small cell lung cancer
Cell Death Discovery
title HDGF promotes gefitinib resistance by activating the PI3K/AKT and MEK/ERK signaling pathways in non-small cell lung cancer
title_full HDGF promotes gefitinib resistance by activating the PI3K/AKT and MEK/ERK signaling pathways in non-small cell lung cancer
title_fullStr HDGF promotes gefitinib resistance by activating the PI3K/AKT and MEK/ERK signaling pathways in non-small cell lung cancer
title_full_unstemmed HDGF promotes gefitinib resistance by activating the PI3K/AKT and MEK/ERK signaling pathways in non-small cell lung cancer
title_short HDGF promotes gefitinib resistance by activating the PI3K/AKT and MEK/ERK signaling pathways in non-small cell lung cancer
title_sort hdgf promotes gefitinib resistance by activating the pi3k akt and mek erk signaling pathways in non small cell lung cancer
url https://doi.org/10.1038/s41420-023-01476-0
work_keys_str_mv AT shuyanhan hdgfpromotesgefitinibresistancebyactivatingthepi3kaktandmekerksignalingpathwaysinnonsmallcelllungcancer
AT zhihuatian hdgfpromotesgefitinibresistancebyactivatingthepi3kaktandmekerksignalingpathwaysinnonsmallcelllungcancer
AT huifangtian hdgfpromotesgefitinibresistancebyactivatingthepi3kaktandmekerksignalingpathwaysinnonsmallcelllungcancer
AT haibohan hdgfpromotesgefitinibresistancebyactivatingthepi3kaktandmekerksignalingpathwaysinnonsmallcelllungcancer
AT junzhao hdgfpromotesgefitinibresistancebyactivatingthepi3kaktandmekerksignalingpathwaysinnonsmallcelllungcancer
AT yannajiao hdgfpromotesgefitinibresistancebyactivatingthepi3kaktandmekerksignalingpathwaysinnonsmallcelllungcancer
AT chunliwang hdgfpromotesgefitinibresistancebyactivatingthepi3kaktandmekerksignalingpathwaysinnonsmallcelllungcancer
AT huifenghao hdgfpromotesgefitinibresistancebyactivatingthepi3kaktandmekerksignalingpathwaysinnonsmallcelllungcancer
AT shanwang hdgfpromotesgefitinibresistancebyactivatingthepi3kaktandmekerksignalingpathwaysinnonsmallcelllungcancer
AT jialeifu hdgfpromotesgefitinibresistancebyactivatingthepi3kaktandmekerksignalingpathwaysinnonsmallcelllungcancer
AT dongxue hdgfpromotesgefitinibresistancebyactivatingthepi3kaktandmekerksignalingpathwaysinnonsmallcelllungcancer
AT hongsun hdgfpromotesgefitinibresistancebyactivatingthepi3kaktandmekerksignalingpathwaysinnonsmallcelllungcancer
AT pingpingli hdgfpromotesgefitinibresistancebyactivatingthepi3kaktandmekerksignalingpathwaysinnonsmallcelllungcancer